«We observed higher rates of neurocognitive decline,
increased symptom burden and a decline in health - related quality of life over time among non-progressing patients treated with bevacizumab,» he says.
According to the WHO, it is the leading cause of ill health and disability worldwide.1 More than 300 million people are estimated to be suffering from depression, corresponding to 4.4 % of the global population.1 Depression is more common among older adults, with a prevalence of 7 % and believed to be underestimated.2 As the world population ages, there will be a corresponding
increase in the number of older adults with depressive
symptoms and associated global health
burden.3
Attention - deficit hyperactivity disorder (ADHD) affects 3 % — 5 % of children and young people under 18 years old.1 The core
symptoms include inattention, impulsivity and hyperactivity leading to significant impairments in academic and social function and
increased risk of substance misuse, unemployment, criminality and mental health problems.2 3 Early treatment is crucial to improve
symptoms and reduce the
burden on the family and wider social and healthcare systems.4 With the
increasing rates of diagnosis of ADHD, spending on ADHD medication has
increased sevenfold between 1998 and 2005,5 and expenditure on medication treatment costs in the UK is now estimated at # 78 million per year.5 6 This has placed
increasing financial
burden on health services and highlighted the need for more efficient and cost - effective services to diagnose and treat the condition.